Nabriva Therapeutics

King of Prussia,  PA 
United States
  • Booth: 3023

Nabriva Therapeutics  is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.  Nabriva Therapeutics  received  U.S. Food and Drug Administration  approval for XENLETA™ (lefamulin), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).  Nabriva Therapeutics  is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.


For Technical Support with this webpage, please contact support.